JNJ Q4 net earnings down 17%, revenue up 5.3% to $22.52B; adjusted EPS $2.04

JOHNSON & JOHNSON

2024-FY EPS reported $5.79 revenue$88,821,000,000

Q4 sales $22.52B, +5.3% YoY; net earnings $3.43B, -17% from $4.13B; diluted EPS $1.41.
Adjusted net earnings $4.95B, adjusted EPS $2.04, down 10.9% from $2.29.
Innovative Medicine (ex-COVID) sales $14.33B (+4.8%); MedTech sales $8.19B (+6.7%).
R&D expense rose 18.3% to $5.30B; operating margin contracted to 17.3% from 22.6%.
Full-year sales $88.82B, +4.3% vs $85.16B; ex-COVID sales +5.5%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.